Biosensors

Lateral flow assays (LFAs) are among the most successful technologies for point-of-care and at-home testing, but further advances are needed to reduce costs and accelerate development. Alpaca-derived nanobodies (Nbs), single-domain antibody fragments, are promising immunoassay reagents across diverse applications. Their small size and ease of recombinant production make them particularly well suited for diagnostics. Here, we present a paper-based LFA targeting the SARS-CoV-2 nucleocapsid (N) protein that exclusively uses Nbs for direct antigen detection. We also demonstrate in-house synthesis of Nb-coated gold nanoparticles, enabling instrument-free visual readout and detection of N protein down to 40 ng/mL. This design avoids components that require mammalian cell culture and can be produced entirely from in-house reagents, simplifying manufacturing and lowering component costs. Because the assay is read visually without an external reader, it is well suited for deployment in resource-limited settings. Together, these results highlight the speed and practicality of developing Nb-based LFAs and suggest a broadly applicable strategy for detecting other clinically important disease biomarkers.

Hexavalent chromium (Cr(VI)) is a high-priority environmental pollutant due to its strong oxidizing properties, which cause DNA damage and other severe health effects. Conventional detection methods are often costly and lack real-time monitoring capabilities, creating a strong demand for cost-effective, real-time biosensors that meet industrial requirements. In this study, we developed a novel biosensor for continuous Cr(VI) monitoring using a single-chamber microbial fuel cell (MFC). The biological element is an engineered Escherichia coli strain (ChrA-ChrB-E. coli), constructed by introducing Cr(VI)-resistant (ChrA) and Cr(VI)-reducing (ChrB) genes. The presence of Cr(VI) affects bacterial metabolism and electron transfer within the MFC, generating a measurable signal proportional to the contaminant’s concentration. The biosensor demonstrated robust performance and characteristics. The recombinant strain retained functional activity after 450 days of storage at −20 °C. The system exhibited high sensitivity and excellent linearity (R² ≥ 0.999) across a broad Cr(VI) concentration range of 0.015–200 mg/L. During continuous monitoring of chrome tanning and electroplating wastewater, measurements deviated by less than 2.33% from the standard diphenylcarbazide (DPC) method; electroplating deviation was further reduced to −0.69% with EDTA pretreatment. In fishery water, the deviation was higher (−7.12%) due to dissolved oxygen (DO) interference but was reduced to −0.75% after mechanical stirring to remove DO. The biofilm bacterial community remained highly stable over six months in both wastewater types, with the inoculated ChrA-ChrB-E. coli strain maintaining dominance (>99.6%). These results substantiate the feasibility of using this biosensor for continuous, online, real-time detection of Cr(VI) in actual wastewater environments.

Early detection of cancer biomarkers in blood is critical for improving patient outcomes; however, conventional immunoassays often rely on complex instrumentation and are not well suited for point-of-care testing or multiplexed analysis. Herein, we present a dual-mode colorimetric–surface-enhanced Raman scattering (SERS) lateral flow immunoassay (LFIA) platform for multiplexed detection of cancer biomarkers, employing elongated rod-shaped silver nanoshells (ERNSs) as SERS nanotags. The ERNS features a rough Ag shell with internally incorporated Raman labeling compounds (RLCs), enabling plasmonic extinction for visual readout and strong SERS signals for quantitative analysis while preserving the external metal surfaces for efficient antibody conjugation. Leveraging these advantages, a multiplex LFIA capable of simultaneously detecting prostate-specific antigen (PSA) and carbohydrate antigen 19-9 (CA19-9) on a single strip was successfully demonstrated. Visual inspection enabled rapid discrimination of samples at or near clinically relevant cut-off levels, while Raman analysis achieved limits of detection of 8.0 × 10⁻³ ng/mL for PSA and 5.4 × 10⁻² U/mL for CA19-9, corresponding to approximately 500-fold and 685-fold lower concentrations than their respective clinical thresholds. This ERNS-based colorimetric–SERS LFIA integrates rapid screening and highly sensitive quantification within a single platform and offers a versatile nanoprobe design strategy for multiplex biomarker detection and liquid biopsy-based diagnostic applications, with potential relevance to point-of-care settings.